CRP and rheumatoid arthritis: E.g., Marsal et al. (2021) innovatively boosted the taVNS stimulator to 2 kHz for the treatment of rheumatoid arthritis disease, and after 12 weeks of treatment, the mean DAS28-CRP significantly decreased in 27 patients compared to baseline, demonstrating that a 100-fold higher treatment frequency was more effective in patients with rheumatoid arthritis than the conventional 20 Hz.